BC |
Breast cancer |
HER-2+ BC |
Human epidermal growth factor receptor-2 overexpressing breast cancer |
NPs |
Nanoparticles |
EGFR |
Epidermal growth factor receptor |
AKT |
Protein kinase B, PKB |
PI3K |
Phosphoinositide 3-kinase |
MAPK |
Mitogen-activated protein kinase |
IHC |
Immunohistochemistry |
FISH |
Fluorescence in situ hybridization |
mAb |
Monoclonal antibodies |
TZ |
Trastuzumab |
DFS |
Disease-free survival |
OS |
Overall survival |
ADCC |
Antibody-Dependent Cellular Cytotoxicity |
T-DM1, Kadcyla®
|
Trastuzumab emtansine |
ADCs |
Antibody-drug conjugates, anticancer drugs |
PFS |
Progression-free survival |
PTEN |
Phosphatase and tensin homolog |
TKIs |
Tyrosine kinase inhibitors |
pCR |
Pathological complete response |
TILs |
Tumor-infiltrating lymphocytes |
PEI |
Polyethylenimine |
PLGA |
Poly (D,L-lactide-co-glycolide) |
sdAb |
Single-domain antibodies |
VH |
Human immunoglobulin heavy chain |
Fab |
Antibody fragments |
TmAb |
Fab obtained by papain cleavage of TZ |
PmAb |
Fab obtained by papain cleavage of panitumumab |
scFv |
Single chain variable fragments |
DOX |
Doxorubicin |
PTX |
Paclitaxel |
PCI |
Photochemical Internalization |
siRNA |
Short interfering RNA |
PTT |
Photothermal therapy |
GNRs |
Gold nanorods |
AuNPs |
Gold nanoparticles |
PK |
Pharmacokinetic |
XBP1 |
X-box binding protein 1 |
PDT |
Photodynamic therapy |
Hapt |
Aptamer |
IHC |
Immunohistochemistry |
CISH |
Chromogenic in-situ hybridization |
CT |
Computerized tomography |
PET |
Positron emission tomography |
SPECT |
Single photon emission computed tomography |
US |
Ultrasounds |
MRI |
Magnetic resonance imaging |
SPIONs |
Super paramagnetic iron oxide nanoparticles |
FGS |
Fluorescence guided surgery |
QDs |
Quantum dots |
Cy |
Cyanine |
BSA |
Bovine serum albumin |
EPR |
Enhanced Permeation and Retention |
PAMAM |
Polyamidoamine |
SERS |
Surface-enhanced Raman scattering |
SELEX |
Systematic evolution of ligands by exponential enrichment |